Miraa Amendment Bill Faces Fierce Resistance From Pharmaceutical Society Of Kenya
PSK opposes bill excluding miraa's cathinone, citing health risks and international law violations.
Breaking News
Jul 29, 2024
Mrudula Kulkarni

The leadership of the Pharmaceutical Society of Kenya's
Coast branch has expressed firm opposition to the Narcotics, Drugs and
Psychotropic Substances Control Amendment Bill, 2024 currently under
consideration by the Senate. Murtaza Mohamed, chairperson of the PSK Coast
branch, highlighted that the proposed legislation seeks to exclude cathinone
and cathine substances found in miraa from being categorized as psychotropic
substances. He cautioned that these substances can pose serious health risks to
individuals. Mohamed further noted that the amendment appears to prioritize the
economic interests of the miraa industry, which provides essential livelihoods
for many Kenyans.
He said in a statement, “The Bill argues that the
classification of these substances as psychotropic by the National Campaign
Against Alcohol and Drug Abuse
negatively impacts the market for miraa despite governmental efforts to
boost the sector. However, the Pharmaceutical Society of Kenya strongly oppose
this amendment because it contradicts both the Kenyan constitution and
international conventions to which Kenya is a party.”
The miraa crop is globally acknowledged as a psychotropic
substance with potential adverse effects on mental health. Mohamed cautioned
that excluding these substances from the controlled substances list could
result in heightened abuse and related health concerns, ultimately burdening
the government with increased public health expenditures. He added, “We would
like to caution that deregulating cathinone and cathine might lead to an influx
of both natural and synthetic derivatives, complicating enforcement and public
health efforts.”
Mohamed pointed out that although the proposed legislation
aims to enhance the miraa industry by relaxing regulations on its psychoactive
elements, it is met with substantial resistance due to health risks and
possible violations of international law. He emphasized that gaining access to
the international market for miraa would necessitate addressing these concerns
at the United Nations level, rather than making unilateral legislative
adjustments.